EP1928506A4 - IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF - Google Patents
IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOFInfo
- Publication number
- EP1928506A4 EP1928506A4 EP06813554A EP06813554A EP1928506A4 EP 1928506 A4 EP1928506 A4 EP 1928506A4 EP 06813554 A EP06813554 A EP 06813554A EP 06813554 A EP06813554 A EP 06813554A EP 1928506 A4 EP1928506 A4 EP 1928506A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- variable domain
- dual variable
- domain immunoglobin
- immunoglobin
- dual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000009977 dual effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12161976A EP2500355A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162014A EP2495257A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12161964A EP2500353A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162041A EP2520588A1 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162029A EP2500358A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162057A EP2500359A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP20120161999 EP2500357A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12161970A EP2500354A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12161953A EP2500352A1 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP20120161985 EP2500356A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70991105P | 2005-08-19 | 2005-08-19 | |
US73289205P | 2005-11-02 | 2005-11-02 | |
PCT/US2006/032398 WO2007024715A2 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobin and uses thereof |
Related Child Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12161970A Division EP2500354A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12161976A Division EP2500355A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162057A Division EP2500359A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12161964A Division EP2500353A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162014A Division EP2495257A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162029A Division EP2500358A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12161953A Division EP2500352A1 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP20120161999 Division EP2500357A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP20120161985 Division EP2500356A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1928506A2 EP1928506A2 (en) | 2008-06-11 |
EP1928506A4 true EP1928506A4 (en) | 2009-10-21 |
Family
ID=41078242
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06813554A Withdrawn EP1928506A4 (en) | 2005-08-19 | 2006-08-18 | IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF |
EP12161953A Withdrawn EP2500352A1 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162014A Withdrawn EP2495257A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162041A Withdrawn EP2520588A1 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12161953A Withdrawn EP2500352A1 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162014A Withdrawn EP2495257A3 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
EP12162041A Withdrawn EP2520588A1 (en) | 2005-08-19 | 2006-08-18 | Dual variable domain immunoglobulin and uses thereof |
Country Status (16)
Country | Link |
---|---|
EP (4) | EP1928506A4 (ko) |
JP (1) | JP5364870B2 (ko) |
KR (2) | KR20130108481A (ko) |
CN (1) | CN101370525B (ko) |
AU (1) | AU2006283532B2 (ko) |
BR (1) | BRPI0615026A8 (ko) |
CA (1) | CA2618482C (ko) |
IL (2) | IL189543A (ko) |
MY (1) | MY169746A (ko) |
NO (1) | NO20081354L (ko) |
NZ (2) | NZ612578A (ko) |
RU (2) | RU2515108C2 (ko) |
SG (1) | SG2014010029A (ko) |
TW (1) | TWI323734B (ko) |
WO (1) | WO2007024715A2 (ko) |
ZA (2) | ZA201100659B (ko) |
Families Citing this family (519)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002051438A2 (en) | 2000-12-22 | 2002-07-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (rgm) and its modulators |
TW200714610A (en) | 2005-02-16 | 2007-04-16 | Univ Maryland | CXCR3 is a gliadin receptor |
JP2012228248A (ja) * | 2005-08-19 | 2012-11-22 | Abbott Lab | 二重可変ドメイン免疫グロブリン及びその使用 |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
CA2624562A1 (en) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use |
ES2415666T3 (es) | 2007-02-01 | 2013-07-26 | Acceleron Pharma, Inc. | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama |
TW201934141A (zh) | 2007-02-09 | 2019-09-01 | 美商艾瑟勒朗法瑪公司 | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
KR20140001229A (ko) | 2007-03-30 | 2014-01-06 | 아보트 러보러터리즈 | 숙주 세포에서 재조합 단백질의 발현을 증강시키기 위한 재조합 발현 벡터 요소(rEVE) |
WO2008134659A2 (en) | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
EP2167669A2 (en) * | 2007-05-31 | 2010-03-31 | Genmab A/S | Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals |
AU2008265983B2 (en) | 2007-06-14 | 2013-06-20 | Galactica Pharmaceuticals, Inc. | RAGE fusion proteins |
CN101743473B (zh) * | 2007-06-22 | 2014-03-19 | 北海道公立大学法人札幌医科大学 | 移植物抗宿主疾病的检查及治疗方法 |
EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
EP2178914A2 (en) * | 2007-08-15 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
EP2207562B1 (en) | 2007-09-18 | 2017-05-31 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
AU2008328785A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
GB2468232B (en) | 2007-11-30 | 2012-10-24 | Glaxo Group Ltd | Antigen-bindng constructs |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
EA021967B1 (ru) | 2008-01-03 | 2015-10-30 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
CN102065892A (zh) * | 2008-01-30 | 2011-05-18 | 雅培制药有限公司 | 用于使抗体片段结晶的组合物和方法 |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
EP2281845B1 (en) | 2008-04-25 | 2020-09-02 | Kyowa Kirin Co., Ltd. | Stable polyvalent antibody |
KR20110014607A (ko) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
UY31861A (es) | 2008-06-03 | 2010-01-05 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
MX2010013239A (es) * | 2008-06-03 | 2011-02-24 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
CA2729749A1 (en) * | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | Tnf-a antagonist multi-target binding proteins |
MX2010014574A (es) * | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
WO2010028796A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
PL2334705T3 (pl) | 2008-09-26 | 2017-06-30 | Ucb Biopharma Sprl | Produkty biologiczne |
PL2346994T3 (pl) | 2008-09-30 | 2022-04-19 | Ablexis, Llc | Myszy knock-in do wytwarzania chimerycznych przeciwciał |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
DK2894165T3 (da) | 2008-11-10 | 2023-03-20 | Alexion Pharma Inc | Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser |
CN102341411A (zh) | 2008-12-31 | 2012-02-01 | 比奥根艾迪克Ma公司 | 抗-淋巴细胞毒素抗体 |
SG172855A1 (en) * | 2009-01-29 | 2011-08-29 | Abbott Lab | Il-1 binding proteins |
US20110305692A1 (en) * | 2009-02-24 | 2011-12-15 | Glaxo Group Limited | Antigen-binding contructs |
NZ611324A (en) * | 2009-03-05 | 2015-02-27 | Abbvie Inc | Il-17 binding proteins |
JP2012520469A (ja) * | 2009-03-12 | 2012-09-06 | キャンサー・プリヴェンション・アンド・キュア,リミテッド | 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療の方法並びにそのキット |
CA2757095C (en) | 2009-03-30 | 2020-04-14 | Acceleron Pharma Inc. | Bmp-alk3 antagonists and uses for promoting bone growth |
RU2598248C2 (ru) | 2009-04-02 | 2016-09-20 | Роше Гликарт Аг | Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab |
WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
CN102361884A (zh) | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-2/抗-c-Met抗体 |
PE20120550A1 (es) | 2009-04-07 | 2012-05-21 | Roche Glycart Ag | ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
BRPI1012195A2 (pt) * | 2009-05-01 | 2018-04-24 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
KR20120044294A (ko) * | 2009-05-01 | 2012-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
WO2010129406A2 (en) * | 2009-05-04 | 2010-11-11 | The Johns Hopkins University | Methods of promoting muscle growth |
TW201100543A (en) | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
AU2010264520A1 (en) | 2009-06-23 | 2012-01-19 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
UY32870A (es) * | 2009-09-01 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
RU2573915C2 (ru) | 2009-09-16 | 2016-01-27 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применение |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
RU2012119756A (ru) | 2009-10-15 | 2013-11-20 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
AU2010318316B2 (en) * | 2009-11-11 | 2016-01-14 | Astellas Pharma Inc. | Antibodies specific for Claudin 6 (CLDN6) |
MX346912B (es) * | 2009-12-07 | 2017-04-05 | Univ Leland Stanford Junior | Metodos para mejorar terapia con anticuerpos antitumor. |
WO2011070045A1 (en) | 2009-12-08 | 2011-06-16 | Abbott Gmbh & Co. Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
JP5234666B2 (ja) * | 2009-12-11 | 2013-07-10 | 国立大学法人大阪大学 | 乾癬の判定のための測定方法 |
US20130059890A1 (en) * | 2009-12-18 | 2013-03-07 | Sydney West Area Health Service | Antiviral agents |
AR079704A1 (es) * | 2009-12-23 | 2012-02-15 | Genentech Inc | Anticuerpos anti-bv8 y sus usos |
CA2786692A1 (en) | 2010-01-11 | 2011-07-14 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
DK2666872T3 (en) * | 2010-02-05 | 2016-07-25 | Astute Medical Inc | Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency |
WO2011109298A2 (en) | 2010-03-02 | 2011-09-09 | Abbott Laboratories | Therapeutic dll4 binding proteins |
TW201144437A (en) | 2010-03-03 | 2011-12-16 | Boehringer Ingelheim Int | A-beta binding polypeptides |
WO2011115812A2 (en) * | 2010-03-16 | 2011-09-22 | Advanced Technologies And Regenerative Medicine, Llc | Affinity peptides toward bmp-2 |
TR201903279T4 (tr) | 2010-03-25 | 2019-03-21 | Ucb Biopharma Sprl | Disülfür stabilize edilmiş DVD-IG molekülleri. |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
CA3006800C (en) | 2010-03-31 | 2022-10-04 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
RU2630663C9 (ru) * | 2010-04-15 | 2017-11-29 | Проджиникс Фармасьютикалс, Инк. | Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний |
SI2563813T1 (sl) | 2010-04-30 | 2015-12-31 | Alexion Pharmaceuticals, Inc. | Protitelesa anti-C5A in postopki uporabe protiteles |
CN103237811A (zh) | 2010-05-06 | 2013-08-07 | 诺瓦提斯公司 | 用于治疗性低密度脂蛋白相关蛋白质6(lrp6)多价抗体的组合物及使用方法 |
CA2798432A1 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
UY33386A (es) * | 2010-05-14 | 2011-12-30 | Abbott Laboratoires | Proteínas de unión a il-1 |
CA2803588A1 (en) | 2010-06-22 | 2011-12-29 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the c3d fragment of complement component 3 |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
AU2014246410B2 (en) * | 2010-08-03 | 2016-06-16 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2012021773A1 (en) | 2010-08-13 | 2012-02-16 | Genentech, Inc. | Antibodies to il-1beta and il-18, for treatment of disease |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
CN105481983B (zh) | 2010-09-09 | 2021-09-03 | 辉瑞公司 | 4-1bb结合分子 |
CN101926998B (zh) * | 2010-09-10 | 2013-09-04 | 中国科学院水生生物研究所 | 肾上腺素受体激动剂诱导胚胎型珠蛋白表达及其用途 |
WO2012057765A1 (en) * | 2010-10-28 | 2012-05-03 | The Board Of Regents Of The University Of Texas System | Recombinant anti-cd19 monoclonal antibodies |
TWI619811B (zh) | 2010-11-08 | 2018-04-01 | 諾華公司 | 趨化細胞素受體結合多肽 |
WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
US20130236467A1 (en) | 2010-11-24 | 2013-09-12 | Jeremy Griggs | Multispecific antigen binding proteins targeting hgf |
JP6009455B2 (ja) * | 2010-12-21 | 2016-10-19 | アッヴィ・インコーポレイテッド | Il−1アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用 |
WO2012088094A2 (en) * | 2010-12-21 | 2012-06-28 | Abbott Laboratories | Il-1 binding proteins |
EP2654792A4 (en) * | 2010-12-22 | 2016-05-11 | Abbvie Inc | HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
WO2012094623A2 (en) * | 2011-01-07 | 2012-07-12 | Abbott Laboratories | Anti-il-12/il-23 antibodies and uses thereof |
DK2665749T3 (en) | 2011-01-19 | 2016-03-21 | Cantargia Ab | Anti-il1rap antibodies and their use for the treatment of solid tumors |
US9447187B2 (en) | 2011-02-03 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
RU2015134562A (ru) * | 2011-02-08 | 2018-12-24 | Эббви Инк. | Лечение остеоартрита и боли |
CN102188707B (zh) * | 2011-02-25 | 2015-08-05 | 中国医学科学院基础医学研究所 | Il-17抑制剂在制备治疗流感的药物中的用途 |
EP2681239B8 (en) | 2011-02-28 | 2015-09-09 | F. Hoffmann-La Roche AG | Antigen binding proteins |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
CN103649118A (zh) | 2011-03-01 | 2014-03-19 | 安进公司 | 双特异性结合剂 |
CN102757503A (zh) * | 2011-04-28 | 2012-10-31 | 中国人民解放军第二军医大学 | 人前列腺凋亡反应蛋白4与凋亡素2配体融合蛋白的制法和用途 |
CA2837169C (en) | 2011-05-24 | 2021-11-09 | Zyngenia, Inc. | Multispecific complexes comprising angiopoietin-2-binding peptide and their uses |
CN102253220B (zh) * | 2011-06-07 | 2014-04-09 | 复旦大学附属中山医院 | 用于诊断慢性阻塞性肺病急性加重期的试剂盒 |
RS57024B1 (sr) | 2011-06-10 | 2018-05-31 | Medimmune Ltd | Anti-pseudomonas psl vezujući molekuli i njihova upotreba |
CN102268089A (zh) * | 2011-07-05 | 2011-12-07 | 上海交通大学 | Agr2阻断抗体及其用途 |
CN104302780B (zh) * | 2011-08-05 | 2017-04-12 | 艾克斯-马赛大学 | 纤维变性易感性il22ra2基因及其用途 |
PE20141521A1 (es) * | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
RU2605390C2 (ru) | 2011-08-23 | 2016-12-20 | Рош Гликарт Аг | Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения |
EP2758435A1 (en) | 2011-09-23 | 2014-07-30 | Roche Glycart AG | Bispecific anti-egfr/anti igf-1r antibodies |
EP2771360A1 (en) | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Immunobinders directed against sclerostin |
MX2014005411A (es) | 2011-11-04 | 2015-02-12 | Novartis Ag | Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
US9580509B2 (en) * | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
MX2014005566A (es) | 2011-11-07 | 2014-10-14 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
CN104080797A (zh) * | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
KR102159109B1 (ko) * | 2011-11-16 | 2020-09-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 항 il-36r 항체 |
MX356933B (es) | 2011-12-14 | 2018-06-20 | Abbvie Deutschland | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. |
CA2855840C (en) | 2011-12-14 | 2023-08-29 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
EP2797956A2 (en) * | 2011-12-30 | 2014-11-05 | Abbvie Inc. | Dual variable domain immunoglobulins against receptors |
MX2014008101A (es) | 2011-12-30 | 2014-09-25 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17. |
NZ714482A (en) | 2012-01-27 | 2017-08-25 | Abbvie Inc | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
IL311502A (en) * | 2012-02-27 | 2024-05-01 | Ablynx Nv | CX3CR1 binding polypeptides |
GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
BR112014024903A2 (pt) | 2012-04-05 | 2017-07-11 | Hoffmann La Roche | anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos |
WO2013180834A2 (en) | 2012-04-06 | 2013-12-05 | Omeros Corporation | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
ES2864857T3 (es) | 2012-06-18 | 2021-10-14 | Omeros Corp | Composiciones y métodos para la inhibición de MASP-1 y/o MASP-2 y/o MASP-3 para el tratamiento de diversas enfermedades y trastornos |
MX2014014804A (es) | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo. |
MX354862B (es) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes. |
SI2869848T1 (sl) | 2012-07-04 | 2017-01-31 | F. Hoffmann-La Roche Ag | Kovalentno vezani konjugati antigen-protitelo |
EP2870180B1 (en) | 2012-07-04 | 2024-08-28 | F. Hoffmann-La Roche AG | Anti-biotin antibodies and methods of use |
BR112014030843A2 (pt) | 2012-07-04 | 2019-10-15 | Hoffmann La Roche | anticorpo anti-teofilina, formulação farmacêutica e uso do anticorpo |
AR091755A1 (es) | 2012-07-12 | 2015-02-25 | Abbvie Inc | Proteinas de union a il-1 |
AR092027A1 (es) | 2012-07-13 | 2015-03-18 | Roche Glycart Ag | Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares |
JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
RU2015117393A (ru) | 2012-10-08 | 2016-12-10 | Роше Гликарт Аг | Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения |
TW201811825A (zh) | 2012-11-01 | 2018-04-01 | 美商艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
EP2935589A1 (en) | 2012-12-18 | 2015-10-28 | Novartis AG | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
JO3519B1 (ar) * | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
CN103103197A (zh) * | 2013-01-30 | 2013-05-15 | 百奇生物科技(苏州)有限公司 | 抗cd138单克隆抗体可变区序列及其制备方法和应用 |
PL2958943T3 (pl) | 2013-02-20 | 2020-04-30 | The Trustees Of The University Of Pennsylvania | Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
NZ708182A (en) | 2013-02-26 | 2019-08-30 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) * | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
AU2014236769B2 (en) * | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
BR112015023752B1 (pt) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
TW201512219A (zh) | 2013-03-15 | 2015-04-01 | Abbvie Inc | 針對IL-1β及/或IL-17之雙特異性結合蛋白 |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
WO2014189306A1 (ko) * | 2013-05-22 | 2014-11-27 | 메타볼랩(주) | 항 TNF-α/CXCL10 이중 타겟 항체 및 그의 용도 |
KR102363220B1 (ko) * | 2013-07-05 | 2022-02-15 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
CN104341504B (zh) | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
CN104231086B (zh) * | 2013-08-27 | 2019-12-13 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
CN103467605B (zh) * | 2013-09-05 | 2015-02-04 | 武汉友芝友生物制药有限公司 | 一种cd3抗原及其制备方法和用途 |
WO2015039212A1 (en) | 2013-09-17 | 2015-03-26 | University Health Network (Uhn): Technology Development And Commercialization | Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
EP3055329B1 (en) | 2013-10-11 | 2018-06-13 | F. Hoffmann-La Roche AG | Multispecific domain exchanged common variable light chain antibodies |
CN104592390B (zh) * | 2013-10-30 | 2017-11-10 | 上海张江生物技术有限公司 | 一类双特异重组抗HBsAg抗体、其制备方法及用途 |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
CN116478927A (zh) | 2013-12-19 | 2023-07-25 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
JP6608827B2 (ja) | 2013-12-20 | 2019-11-20 | エフ.ホフマン−ラ ロシュ アーゲー | ヒト化抗タウ(pS422)抗体及び使用方法 |
CN105873615B (zh) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | 共价连接的helicar-抗helicar抗体缀合物及其用途 |
RU2682754C2 (ru) | 2014-01-03 | 2019-03-21 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью |
PL3089996T3 (pl) | 2014-01-03 | 2021-12-13 | F. Hoffmann-La Roche Ag | Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg |
AU2015205370B2 (en) | 2014-01-10 | 2017-11-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Hydroxy formamide derivatives and their use |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
EP3101035B1 (en) * | 2014-01-28 | 2021-10-06 | Beijing Hanmi Pharmaceutical Co., Ltd. | Bifunctional fusion protein, preparation method therefor, and use thereof |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN106030308B (zh) * | 2014-02-24 | 2019-07-02 | 免疫制药股份责任有限公司 | 用于肺癌的生物标记物、相关的方法和试剂盒 |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
EP3119425B1 (en) | 2014-03-15 | 2020-09-23 | Novartis AG | Regulatable chimeric antigen receptor |
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
EP3122780B1 (en) | 2014-03-27 | 2022-03-09 | Bird Rock Bio, Inc. | Antibodies that bind human cannabinoid 1 (cb1) receptor |
DK3129470T3 (da) | 2014-04-07 | 2021-07-05 | Novartis Ag | Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor |
RU2718692C2 (ru) | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
US20170327553A1 (en) | 2014-06-25 | 2017-11-16 | Novartis Ag | Compositions and methods for long acting proteins |
WO2015198243A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
EP3161001A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置 |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
MX2017001556A (es) | 2014-08-04 | 2017-05-15 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t. |
PE20170287A1 (es) | 2014-08-07 | 2017-04-05 | Novartis Ag | Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso |
TW201613977A (en) | 2014-08-07 | 2016-04-16 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | GFRα−4キメラ抗原受容体を用いる癌の治療 |
SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
GB201414823D0 (en) * | 2014-08-20 | 2014-10-01 | Argen X Bv | Multispecific antibodies |
US20170281624A1 (en) | 2014-09-13 | 2017-10-05 | Novartis Ag | Combination therapies of alk inhibitors |
PL3194443T3 (pl) | 2014-09-17 | 2022-01-31 | Novartis Ag | Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej |
BR112017006602A2 (pt) | 2014-10-01 | 2017-12-19 | Medimmune Llc | método de conjugação de um polipeptídeo |
AU2015349610B2 (en) * | 2014-11-17 | 2021-08-26 | B-Creative Sweden Ab | Method of treating or preventing stroke |
KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
LT3789402T (lt) | 2014-11-20 | 2022-09-26 | F. Hoffmann-La Roche Ag | Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus |
CN105669867A (zh) * | 2014-11-21 | 2016-06-15 | 上海中信国健药业股份有限公司 | 抗gitr/ctla-4双特异性抗体及其制备方法和用途 |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
US10982008B2 (en) * | 2014-12-05 | 2021-04-20 | Merck Patent Gmbh | Domain-exchanged antibody |
BR112017011893A2 (pt) | 2014-12-05 | 2018-07-24 | City Of Hope | células t modificadas no receptor de antígeno quimérico direcionado para cs1 |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
CA3197849A1 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2016118921A1 (en) | 2015-01-24 | 2016-07-28 | Abbvie, Inc. | Compositions and methods for treating psoriatic arthritis |
SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
KR102329836B1 (ko) | 2015-01-26 | 2021-11-19 | 셀렉티스 | 암 면역치료를 위한 항-CLL1 특이적 단일-체인 키메라 항원 수용체들(scCARS) |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
CN105988009B (zh) * | 2015-02-28 | 2018-03-13 | 复旦大学附属华山医院 | Netrin‑4在制备检测胃癌及预后标志物的制剂中的用途 |
EP3070103A1 (en) * | 2015-03-19 | 2016-09-21 | Institut Hospitalier Universitaire De Strasbourg | Anti-Claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma |
CN107646039B (zh) * | 2015-04-02 | 2022-04-15 | 埃博灵克斯股份有限公司 | 具有有效抗hiv活性的双特异性cxcr4-cd4多肽 |
HUE059218T2 (hu) | 2015-04-08 | 2022-11-28 | Novartis Ag | CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel |
CA2982996A1 (en) | 2015-04-17 | 2016-10-20 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
BR112017023158A2 (pt) | 2015-04-30 | 2018-07-24 | Harvard College | anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos |
CA2984589A1 (en) | 2015-05-01 | 2016-11-10 | The University Of British Columbia | Biomarkers for the detection of acute rejection in heart transplantation |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
CN104987421A (zh) * | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
CN114634943A (zh) | 2015-05-18 | 2022-06-17 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
WO2016193496A1 (en) | 2015-06-04 | 2016-12-08 | Ospedale San Raffaele Srl | Igfbp3 and uses thereof |
CA2988011C (en) | 2015-06-04 | 2021-03-23 | Ospedale San Raffaele Srl | Inhibitor of igfbp3/tmem219 axis and diabetes |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
TWI737614B (zh) | 2015-06-11 | 2021-09-01 | 博錸生技股份有限公司 | 已編碼微載體及其製造方法以及用以進行多工分析之包含該等已編碼微載體之套件 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
EP3744732A1 (en) | 2015-06-24 | 2020-12-02 | F. Hoffmann-La Roche AG | Humanized anti-tau(ps422) antibodies and methods of use |
EA036821B1 (ru) | 2015-07-06 | 2020-12-23 | Юсб Биофарма Срл | Тау-связывающие антитела |
SG10202010735PA (en) | 2015-07-06 | 2020-11-27 | UCB Biopharma SRL | Tau-binding antibodies |
JP7146632B2 (ja) | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
MX2018001227A (es) | 2015-07-30 | 2018-03-26 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas. |
WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
MY186352A (en) | 2015-09-09 | 2021-07-15 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
PT3347377T (pt) | 2015-09-09 | 2021-04-30 | Novartis Ag | Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos |
JP2018528218A (ja) | 2015-09-11 | 2018-09-27 | アンドリアン、ブルース | 組換えグリコシル化エクリズマブおよびエクリズマブ変異体 |
CN108473576A (zh) | 2015-09-11 | 2018-08-31 | 艾伯维公司 | 用于治疗复发形式的多发性硬化的方法 |
CA2998740A1 (en) * | 2015-09-17 | 2017-03-23 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
KR20180053322A (ko) | 2015-09-21 | 2018-05-21 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
AU2016328279A1 (en) * | 2015-09-24 | 2018-05-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
CN108513615B (zh) | 2015-09-30 | 2022-03-08 | 鸟石生物公司 | 结合人大麻素1(cb1)受体的抗体 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
WO2017055389A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
US11203634B2 (en) | 2015-10-07 | 2021-12-21 | Alexion Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody |
RU2755724C2 (ru) * | 2015-11-18 | 2021-09-20 | Мерк Шарп И Доум Корп. | Pd1/ctla4-связывающие вещества |
LT3380620T (lt) | 2015-11-23 | 2024-09-10 | Novartis Ag | Optimizuoti lentivirusiniai pernešimo vektoriai ir jų panaudojimas |
EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
UA125611C2 (uk) | 2015-12-14 | 2022-05-04 | Макродженікс, Інк. | Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
CN106918699B (zh) * | 2015-12-25 | 2018-07-06 | 广州瑞博奥生物科技有限公司 | 一种检测肾癌标记物的抗体芯片试剂盒 |
ES2944597T3 (es) | 2015-12-30 | 2023-06-22 | Novartis Ag | Terapias con células efectoras inmunitarias de eficacia mejorada |
WO2017113181A1 (zh) * | 2015-12-30 | 2017-07-06 | 深圳先进技术研究院 | IgG杂合型抗TNFα和IL-17A双特异性抗体 |
PL3400246T3 (pl) | 2016-01-08 | 2021-03-08 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3 |
JP7022993B2 (ja) | 2016-01-11 | 2022-02-21 | インヒブルクス インコーポレイテッド | 多価かつ多重特異性の41bb結合融合タンパク質 |
SG11201805422WA (en) * | 2016-01-11 | 2018-07-30 | Inhibrx Inc | Multivalent and multispecific ox40-binding fusion proteins |
US20210198368A1 (en) | 2016-01-21 | 2021-07-01 | Novartis Ag | Multispecific molecules targeting cll-1 |
CN108495653A (zh) | 2016-01-27 | 2018-09-04 | 免疫医疗有限责任公司 | 用于制备具有定义的糖基化模式抗体的方法 |
CN105481981B (zh) * | 2016-01-27 | 2019-03-19 | 中国人民解放军第二军医大学 | 靶向vegf双特异性抗体及其用途 |
UY37127A (es) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
JP2019513347A (ja) | 2016-03-04 | 2019-05-30 | ノバルティス アーゲー | 複数のキメラ抗原受容体(car)分子を発現する細胞およびその使用 |
HUE061946T2 (hu) | 2016-03-22 | 2023-09-28 | Hoffmann La Roche | Proteáz-aktivált T-sejt bispecifikus molekulák |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
AU2017244108B2 (en) | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
DK3443096T5 (da) | 2016-04-15 | 2024-09-09 | Novartis Ag | Sammensætninger og fremgangsmåder til selektiv ekspression af kimære antigenreceptorer |
EP3442574A4 (en) | 2016-04-15 | 2019-12-11 | MacroGenics, Inc. | NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE |
CN107347014B (zh) * | 2016-05-04 | 2020-12-18 | 中国移动通信集团广东有限公司 | 一种网络故障检测方法和系统 |
GB201608197D0 (en) * | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
AU2017268460B2 (en) | 2016-05-20 | 2023-12-14 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
CA3025329A1 (en) | 2016-06-01 | 2017-12-07 | Abbvie Inc. | Anti-repulsive guidance molecule a (rgma) antagonistic antibodies for treating spinal cord injury and pain |
US20170348442A1 (en) | 2016-06-02 | 2017-12-07 | Washington University | Compositions and methods for detecting ccr2 receptors |
WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
CN106110426B (zh) * | 2016-07-01 | 2019-01-22 | 翁炳焕 | 艾滋病免疫治疗仪 |
WO2018013918A2 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
BR112019001570A2 (pt) | 2016-07-28 | 2019-07-09 | Novartis Ag | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 |
JOP20170154B1 (ar) | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
CN110267677A (zh) | 2016-08-01 | 2019-09-20 | 诺华股份有限公司 | 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症 |
EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP2020501508A (ja) | 2016-09-15 | 2020-01-23 | クアドルセプト バイオ リミテッド | 多量体、四量体および八量体 |
CN107868791B (zh) * | 2016-09-26 | 2021-11-23 | 阿思科力(苏州)生物科技有限公司 | 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用 |
WO2018060301A1 (en) | 2016-09-30 | 2018-04-05 | F. Hoffmann-La Roche Ag | Bispecific antibodies against cd3 |
MX2019003473A (es) | 2016-10-03 | 2019-10-15 | Abbott Lab | Metodos mejorados para evaluar el estado de ubiquitin carboxi-terminal hidrolasa l1 (uch-l1) en muestras de pacientes. |
TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
US11965884B2 (en) | 2016-10-19 | 2024-04-23 | Alexion Pharmaceuticals, Inc. | Method of quantitating unbound C5 in a sample |
JP7173965B2 (ja) | 2016-10-19 | 2022-11-16 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 試料中の非結合C5aの定量化方法 |
JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法 |
CA3044659A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス,インク. | 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法 |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018107125A1 (en) | 2016-12-09 | 2018-06-14 | Seattle Genetics, Inc. | Bivalent antibodies masked by coiled coils |
WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
EP3554343A1 (en) | 2016-12-14 | 2019-10-23 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
CA3045475A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device |
CN110430801B (zh) | 2016-12-14 | 2024-04-30 | 比奥拉治疗股份有限公司 | 使用tnf抑制剂治疗胃肠道疾病 |
WO2018112223A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
CA3046023A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
WO2018112235A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
MX2019006821A (es) | 2016-12-14 | 2019-10-21 | Progenity Inc | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos. |
JP7150723B2 (ja) | 2016-12-14 | 2022-10-11 | ビオラ・セラピューティクス・インコーポレイテッド | 消化管疾病のインテグリン阻害薬による治療 |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
KR102630036B1 (ko) | 2016-12-23 | 2024-01-29 | 마크로제닉스, 인크. | Adam9-결합 분자, 및 이것의 사용 방법 |
ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
JP2020506700A (ja) | 2017-01-31 | 2020-03-05 | ノバルティス アーゲー | 多重特異性を有するキメラt細胞受容体タンパク質を用いた癌の治療 |
EP3585431A4 (en) | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
CN106706930B (zh) * | 2017-02-28 | 2018-11-02 | 扬州诺明哲天医学检验实验室有限公司 | 一种用于帕金森综合症检测的试剂盒 |
CN106596979B (zh) * | 2017-02-28 | 2018-10-09 | 汉氏联合(天津)干细胞研究院有限公司 | 一种用于帕金森综合症检测的试剂盒及其检测方法 |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
WO2018175942A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
EP3600414A1 (en) | 2017-03-30 | 2020-02-05 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
JP2020515579A (ja) | 2017-03-30 | 2020-05-28 | プロジェニティ, インコーポレイテッド | 消化管疾病の生菌生物学的製剤による治療 |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
US20200094031A1 (en) | 2017-03-30 | 2020-03-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
CA3053409A1 (en) | 2017-04-15 | 2018-10-18 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
BR112019022476A2 (pt) | 2017-04-28 | 2020-05-12 | Abbott Laboratories | Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
US11939385B2 (en) | 2017-05-16 | 2024-03-26 | ALX Oncology Inc. | Activatable antibodies and methods of use thereof |
US10866251B2 (en) | 2017-05-25 | 2020-12-15 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
BR112019025387A2 (pt) | 2017-05-30 | 2020-07-07 | Abbott Laboratories | métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces |
WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US20190062428A1 (en) | 2017-06-19 | 2019-02-28 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
JP7454945B2 (ja) | 2017-07-03 | 2024-03-25 | アボット・ラボラトリーズ | 血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法 |
MY202336A (en) | 2017-07-11 | 2024-04-24 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
CN107375904B (zh) * | 2017-08-01 | 2020-11-27 | 无锡市人民医院 | β-arrestin1在防治色素障碍性皮肤病中的应用 |
CN111182951A (zh) | 2017-08-01 | 2020-05-19 | 指南针制药有限责任公司 | 过滤和层析荚以及使用其的方法 |
US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
EA202090739A1 (ru) | 2017-10-13 | 2020-09-07 | Харпун Терапьютикс, Инк. | Белки, связывающие антиген созревания в-клеток |
SG11202003359UA (en) | 2017-10-13 | 2020-05-28 | Harpoon Therapeutics Inc | Trispecific proteins and methods of use |
AR123115A1 (es) | 2017-10-18 | 2022-11-02 | Novartis Ag | Composiciones y métodos para la degradación selectiva de proteínas |
SG11202003177RA (en) | 2017-10-25 | 2020-05-28 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
EP3703751A2 (en) | 2017-11-03 | 2020-09-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
KR102189893B1 (ko) * | 2017-11-15 | 2020-12-11 | (주)에스엘에스바이오 | bPAG1에 특이적으로 결합하는 항체 및 이의 용도 |
WO2019100052A2 (en) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
CN110892266A (zh) | 2017-12-09 | 2020-03-17 | 雅培实验室 | 使用gfap和uch-l1的组合辅助诊断和评价人类受试者中创伤性脑损伤的方法 |
US11022617B2 (en) | 2017-12-09 | 2021-06-01 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) |
AU2018385409A1 (en) | 2017-12-12 | 2020-07-02 | Macrogenics Inc. | Bispecific CD 16-binding molecules and their use in the treatment of disease |
CN109954136B (zh) * | 2017-12-14 | 2023-05-02 | 深圳市中科艾深医药有限公司 | 人sDR5-Fc重组融合蛋白作为脑卒中治疗药物的应用 |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
TW201930358A (zh) | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對tigit之單域抗體及其變異體 |
BR112020010430A2 (pt) | 2017-12-29 | 2020-11-24 | Abbott Laboratories | biomarcadores e métodos inovadores para diagnosticar e avaliar lesão cerebral traumática |
US20190330591A1 (en) | 2018-01-10 | 2019-10-31 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
KR20200120641A (ko) | 2018-01-15 | 2020-10-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
KR20200118065A (ko) | 2018-02-08 | 2020-10-14 | 제넨테크, 인크. | 이중특이적 항원-결합 분자 및 이의 사용 방법 |
EP3762027A4 (en) * | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
AU2019235842B2 (en) | 2018-03-14 | 2022-02-03 | Surface Oncology, Inc. | Antibodies that bind CD39 and uses thereof |
EP3768705A1 (en) | 2018-03-22 | 2021-01-27 | Universität Stuttgart | Multivalent binding molecules |
WO2019183499A1 (en) | 2018-03-22 | 2019-09-26 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
GB201804701D0 (en) | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
CN108404132A (zh) * | 2018-05-11 | 2018-08-17 | 厦门大学 | Ifna4与ifna10基因在克罗恩病中的应用 |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
CN108508216B (zh) * | 2018-06-06 | 2020-08-07 | 暨南大学 | 抗人bFGF纳米抗体检测bFGF的方法及试剂盒 |
WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
EP3806962A1 (en) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma chimeric antigen receptors and uses thereof |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
JP7397444B2 (ja) | 2018-06-26 | 2023-12-13 | 協和キリン株式会社 | コンドロイチン硫酸プロテオグリカン-5に結合する抗体 |
CN112424358A (zh) | 2018-06-26 | 2021-02-26 | 协和麒麟株式会社 | 与细胞粘附分子3结合的抗体 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020033923A1 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antigen binding agents that bind cd277 and uses thereof |
WO2020033925A2 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
EP3833442A2 (en) | 2018-08-09 | 2021-06-16 | Compass Therapeutics LLC | Antibodies that bind cd277 and uses thereof |
EP3837285A1 (en) | 2018-08-13 | 2021-06-23 | Inhibrx, Inc. | Ox40-binding polypeptides and uses thereof |
EP3841120A1 (en) | 2018-08-21 | 2021-06-30 | Citryll B.V. | Antibodies binding to citrullinated histone 2a and/or 4 |
EP3844192A1 (en) | 2018-08-30 | 2021-07-07 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US11590223B2 (en) | 2018-08-31 | 2023-02-28 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies |
EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
WO2020047452A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3849565A4 (en) | 2018-09-12 | 2022-12-28 | Fred Hutchinson Cancer Research Center | REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS |
CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
WO2020069409A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
KR20210078517A (ko) | 2018-10-16 | 2021-06-28 | 유씨비 바이오파마 에스알엘 | 중증근무력증의 치료 방법 |
AU2019379576A1 (en) | 2018-11-13 | 2021-06-03 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US11739160B2 (en) | 2018-12-24 | 2023-08-29 | Sanofi | PseudoFab-based multispecific binding proteins |
SG11202107538VA (en) | 2019-01-16 | 2021-08-30 | Compass Therapeutics Llc | Formulations of antibodies that bind human cd137 and uses thereof |
GB201900732D0 (en) | 2019-01-18 | 2019-03-06 | Ucb Biopharma Sprl | Antibodies |
MX2021009079A (es) | 2019-01-28 | 2022-02-10 | Sanofi Sa | Metodos para tratar el mieloma multiple. |
CN113840618A (zh) * | 2019-02-14 | 2021-12-24 | 太平洋米科生物科技有限公司 | 一种通过调节abcf1进行免疫调节的方法 |
EP3924054A1 (en) | 2019-02-15 | 2021-12-22 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US20220088075A1 (en) | 2019-02-22 | 2022-03-24 | The Trustees Of The University Of Pennsylvania | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
JP2022523204A (ja) | 2019-02-25 | 2022-04-21 | ノバルティス アーゲー | ウイルス送達のためのメソポーラスシリカ粒子組成物 |
US11079395B2 (en) | 2019-03-01 | 2021-08-03 | Abbott Laboratories | Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease |
JP7379654B2 (ja) | 2019-03-15 | 2023-11-14 | カーティザン セラピューティクス,インコーポレーテッド | 抗bcmaキメラ抗原受容体 |
GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
CN109811064B (zh) * | 2019-04-02 | 2023-12-05 | 华南农业大学 | 一种与鸡j亚群禽白血病抗性相关的分子标记及其应用 |
WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
CN110075322B (zh) * | 2019-05-20 | 2021-07-06 | 复旦大学附属妇产科医院 | 一种靶向GnRH受体的近红外荧光成像探针及其制备方法与应用 |
EP3994270A1 (en) | 2019-07-02 | 2022-05-11 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
CN110478474B (zh) * | 2019-08-21 | 2020-06-02 | 启辰生生物科技(珠海)有限公司 | 免疫调节剂、疫苗、细胞及应用 |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
BR112022002351A2 (pt) | 2019-09-16 | 2022-07-19 | Surface Oncology Inc | Composições e métodos de anticorpo anti-cd39 |
CN110627905B (zh) * | 2019-09-18 | 2021-04-27 | 中国医学科学院肿瘤医院 | 靶向vegf与egfr的双功能融合蛋白及其应用 |
MX2022003719A (es) | 2019-09-25 | 2022-04-26 | Surface Oncology Inc | Anticuerpos anti-il-27 y sus usos. |
CN110988354A (zh) * | 2019-11-15 | 2020-04-10 | 同济大学 | 一种分泌蛋白Caspase1在早期心梗诊断试剂中的应用 |
WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
GB201917480D0 (en) | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
JP2023509323A (ja) | 2020-01-06 | 2023-03-08 | ヴァクシネックス, インコーポレイテッド | 抗ccr8抗体及びその使用 |
EP4104187A1 (en) | 2020-02-14 | 2022-12-21 | Novartis AG | Method of predicting response to chimeric antigen receptor therapy |
BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
EP4110376A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
US20230174933A1 (en) | 2020-02-27 | 2023-06-08 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
CN111269326A (zh) | 2020-02-28 | 2020-06-12 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
US11896619B2 (en) | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
RU2763178C2 (ru) * | 2020-03-23 | 2021-12-28 | Акционерное Общество "Р-Фарм" | Антитела для лабораторной диагностики концентрации интерлейкина-11 |
CA3175523A1 (en) | 2020-04-13 | 2021-10-21 | Antti Virtanen | Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample |
MX2022014203A (es) | 2020-05-12 | 2023-02-22 | Lyell Immunopharma Inc | Espaciadores de receptores de antígenos quiméricos (car). |
CN111849910B (zh) | 2020-05-27 | 2021-06-15 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
KR20220166837A (ko) | 2020-06-11 | 2022-12-19 | 난징 바이오흐엥 바이오테크 씨오., 엘티디 | Nk억제 분자를 발현하는 조작된 면역 세포 및 그 용도 |
EP4165169A1 (en) | 2020-06-11 | 2023-04-19 | Novartis AG | Zbtb32 inhibitors and uses thereof |
EP4168447A1 (en) | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibodies binding to cd3 and cd19 |
KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
US20240279353A1 (en) | 2020-07-06 | 2024-08-22 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
JP2023527530A (ja) | 2020-07-15 | 2023-06-29 | 南京北恒生物科技有限公司 | 同種異系移植のための操作された免疫細胞 |
JP2023534214A (ja) | 2020-07-16 | 2023-08-08 | ノバルティス アーゲー | 抗ベータセルリン抗体、その断片、及び多重特異性結合分子 |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
CN114057890A (zh) | 2020-07-31 | 2022-02-18 | 南京北恒生物科技有限公司 | 新型共刺激结构域及其用途 |
JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
WO2022031804A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Laboratories | Improved methods and kits for detecting sars-cov-2 protein in a sample |
GB202012326D0 (en) | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
CN112063588A (zh) | 2020-08-13 | 2020-12-11 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
MX2023002107A (es) | 2020-08-21 | 2023-03-15 | Novartis Ag | Composiciones y metodos para la generacion in vivo de celulas que expresan car. |
CN114163532A (zh) | 2020-09-10 | 2022-03-11 | 南京北恒生物科技有限公司 | 包含新型共刺激结构域的嵌合抗原受体及其用途 |
JP2023546071A (ja) | 2020-10-13 | 2023-11-01 | アルミラル・ソシエダッド・アノニマ | 二重特異性分子およびそれを用いた処置方法 |
CA3197465A1 (en) | 2020-11-02 | 2022-05-05 | UCB Biopharma SRL | Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders |
CN112300282A (zh) | 2020-11-03 | 2021-02-02 | 南京北恒生物科技有限公司 | 靶向cd7的人源化抗体及其用途 |
CN114525259A (zh) | 2020-11-03 | 2022-05-24 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
JP2023549504A (ja) | 2020-11-13 | 2023-11-27 | ノバルティス アーゲー | キメラ抗原受容体(car)発現細胞との組合せ療法 |
WO2022108627A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
CN114524876A (zh) | 2020-11-23 | 2022-05-24 | 南京北恒生物科技有限公司 | 靶向nkg2a的抗体及其用途 |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2022119841A1 (en) | 2020-12-01 | 2022-06-09 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
CN112748247A (zh) * | 2020-12-23 | 2021-05-04 | 复旦大学附属华山医院 | 抗体结合剂在制备白癜风病期辅助检测产品中的应用及白癜风病期鉴定用的检测试剂盒 |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
US20240052029A1 (en) | 2021-01-12 | 2024-02-15 | Bioheng Therapeutics Limited | Ror1-targeting antibody and use thereof |
EP4273175A4 (en) | 2021-02-03 | 2024-08-14 | Bioheng Therapeutics Ltd | NOVEL CHIMERIC ANTIGEN RECEPTOR AND ITS USE |
MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
CN112957472B (zh) * | 2021-02-05 | 2021-11-16 | 无锡市第五人民医院 | 靶向ccl19/ccr7的乙型肝炎免疫治疗剂及其用途 |
AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
CN112961250B (zh) * | 2021-03-01 | 2023-06-06 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
TW202304524A (zh) | 2021-04-10 | 2023-02-01 | 美商普方生物製藥美國公司 | Folr1結合劑、其結合物及使用方法 |
TW202308699A (zh) | 2021-04-23 | 2023-03-01 | 美商普方生物製藥美國公司 | Cd70結合劑、其結合物及其使用方法 |
JP2024515793A (ja) | 2021-04-27 | 2024-04-10 | ノバルティス アーゲー | ウイルスベクター生産システム |
IL308223A (en) | 2021-05-04 | 2024-01-01 | Citryll B V | Prevention of eosinophilic traps |
EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
KR20240005809A (ko) | 2021-05-07 | 2024-01-12 | 서피스 온콜로지, 엘엘씨 | 항-il-27 항체 및 이의 용도 |
EP4341699A1 (en) | 2021-05-18 | 2024-03-27 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
US20240118279A1 (en) | 2021-06-14 | 2024-04-11 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
TW202330598A (zh) * | 2021-06-30 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合baff和il-12/23的抗原結合分子及用途 |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
JP2024531364A (ja) | 2021-08-20 | 2024-08-29 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
CA3230038A1 (en) | 2021-08-31 | 2023-03-09 | Hongwei Zhang | Methods and systems of diagnosing brain injury |
AU2022354059A1 (en) | 2021-09-30 | 2024-03-28 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
CN113884685B (zh) * | 2021-10-18 | 2023-03-14 | 中国农业大学 | 牛结核病血清学诊断标志物及其临床应用 |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
CA3240822A1 (en) | 2021-12-17 | 2023-06-22 | Tony Lee | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
WO2023209568A1 (en) | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
CN117285647A (zh) * | 2022-06-17 | 2023-12-26 | 南京北恒生物科技有限公司 | 靶向ccr8的嵌合抗原受体及其用途 |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
TW202423983A (zh) | 2022-09-15 | 2024-06-16 | 瑞士商諾華公司 | 使用嵌合抗原受體療法的自體免疫性障礙的治療 |
TW202417509A (zh) * | 2022-09-20 | 2024-05-01 | 大陸商雲頂新耀醫藥科技有限公司 | Slit2相關組合物和方法 |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
GB202216503D0 (en) | 2022-11-05 | 2022-12-21 | Quadrucept Bio Ltd | Non-human vertebrates & cells |
WO2024115393A1 (en) | 2022-11-28 | 2024-06-06 | UCB Biopharma SRL | Treatment of fibromyalgia |
US20240200085A1 (en) | 2022-12-15 | 2024-06-20 | Aarhus Universitet | Synthetic activation of multimeric transmembrane receptors |
WO2024153168A2 (en) | 2023-01-19 | 2024-07-25 | Beigene, Ltd. | Anti-cmet antibodies and methods of use |
WO2024183635A1 (en) | 2023-03-03 | 2024-09-12 | Beigene, Ltd. | Muc1 and cd16a antibodies and methods of use |
WO2024183636A1 (en) | 2023-03-03 | 2024-09-12 | Beigene Switzerland Gmbh | Cd16a antibodies and methods of use |
WO2024184812A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 antibodies and methods of use |
WO2024184811A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cd3 multispecific antibodies and methods of use |
WO2024184810A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use |
CN116286669B (zh) * | 2023-03-23 | 2023-09-22 | 江南大学 | 一株分泌托拉塞米单克隆抗体的杂交瘤细胞株及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0517024A2 (de) * | 1991-06-03 | 1992-12-09 | BEHRINGWERKE Aktiengesellschaft | Tetravalente bispezifische Rezeptoren, ihre Herstellung und Verwendung |
WO1995009917A1 (en) * | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
WO2001077342A1 (en) * | 2000-04-11 | 2001-10-18 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2002002781A1 (en) * | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
US20020127231A1 (en) * | 1996-03-28 | 2002-09-12 | Jonathan Schneck | Soluble divalent and multivalent heterodimeric analogs of proteins |
WO2006020258A2 (en) * | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780A (en) | 1848-09-19 | Improvement in preparing shoe-pegs | ||
US500362A (en) | 1893-06-27 | Resistance-box | ||
US225A (en) | 1837-06-03 | Machine fob | ||
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) * | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
AU642932B2 (en) | 1989-11-06 | 1993-11-04 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
JP3854306B2 (ja) | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
ES2181673T3 (es) | 1991-05-01 | 2003-03-01 | Jackson H M Found Military Med | Procedimiento de tratamiento de las enfermedades respiratorias infecciosas. |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
DE4408152A1 (de) | 1994-03-11 | 1995-09-14 | Studiengesellschaft Kohle Mbh | Immobilisierte Lipasen in hydrophoben Sol-Gel-Materialien |
ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
EP0826034A4 (en) | 1995-04-21 | 2002-06-19 | Cell Genesys Inc | PRODUCTION OF LARGE GENOMIC DNA DELETIONS |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
JP2000507912A (ja) | 1995-08-31 | 2000-06-27 | アルカームズ コントロールド セラピューティックス,インコーポレイテッド | 作用剤の徐放性組成物 |
BR9606706A (pt) * | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
BRPI9715219B8 (pt) | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
ES2395214T3 (es) | 1996-03-04 | 2013-02-11 | The Penn State Research Foundation | Materiales y métodos para aumentar la internalización celular |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
WO1998031346A1 (en) | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
CN1238366C (zh) | 1997-01-21 | 2006-01-25 | 综合医院公司 | 利用rna-蛋白融合体筛选蛋白 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
AU2978899A (en) | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
DE69909459T2 (de) * | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
ATE238768T1 (de) | 1998-06-24 | 2003-05-15 | Advanced Inhalation Res Inc | Grosse poröse partikel ausgestossen von einem inhalator |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
PT2112166T (pt) | 1998-12-23 | 2019-01-30 | Pfizer | Anticorpos monoclonais humanos contra ctla-4 |
CA2796140A1 (en) | 1999-03-25 | 2000-09-28 | Jochen Salfeld | Human antibodies that bind human il-12 and methods for producing |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
TWI335336B (ko) | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
KR100812658B1 (ko) | 2000-02-25 | 2008-03-13 | 더 거번먼트 오브 더 유나이티드 스테이츠, 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비스즈 | 향상된 세포독성 및 수율의 항-이지에프알브이 3,에스씨에프브이에스, 이에 기초한 면역독소, 및 이의 이용방법 |
JP2003533187A (ja) | 2000-05-03 | 2003-11-11 | アムジエン・インコーポレーテツド | 治療薬としてのFcドメインを含む修飾ペプチド |
KR100480985B1 (ko) | 2000-05-19 | 2005-04-07 | 이수화학 주식회사 | 표피 성장 인자 수용체에 대한 사람화된 항체 |
JP2004511430A (ja) * | 2000-05-24 | 2004-04-15 | イムクローン システムズ インコーポレイティド | 二重特異性免疫グロブリン様抗原結合蛋白および製造方法 |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
EP1297172B1 (en) | 2000-06-28 | 2005-11-09 | Glycofi, Inc. | Methods for producing modified glycoproteins |
SK1152003A3 (en) | 2000-06-29 | 2003-07-01 | Abbott Lab | Dual specificity antibodies and methods of making and using |
CA2433353C (en) * | 2000-12-28 | 2017-03-21 | Altus Biologics, Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
WO2002097048A2 (en) | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
DE10129336A1 (de) | 2001-06-19 | 2003-01-02 | Basf Ag | Verfahren zur Herstellung von Pyrrolidonen |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
PT1438400E (pt) | 2001-10-01 | 2009-09-10 | Dyax Corp | Vectores de apresentação eucarióticos de cadeias múltiplas e suas utilizações |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
ES2335005T5 (es) | 2003-03-05 | 2013-04-17 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (shasegp), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
JP2007528723A (ja) | 2003-08-22 | 2007-10-18 | メディミューン,インコーポレーテッド | 抗体のヒト化 |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
AU2005233387B2 (en) | 2004-04-15 | 2011-05-26 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2006
- 2006-08-18 WO PCT/US2006/032398 patent/WO2007024715A2/en active Application Filing
- 2006-08-18 KR KR1020137022517A patent/KR20130108481A/ko not_active Application Discontinuation
- 2006-08-18 SG SG2014010029A patent/SG2014010029A/en unknown
- 2006-08-18 MY MYPI2012001921A patent/MY169746A/en unknown
- 2006-08-18 BR BRPI0615026A patent/BRPI0615026A8/pt not_active IP Right Cessation
- 2006-08-18 AU AU2006283532A patent/AU2006283532B2/en not_active Ceased
- 2006-08-18 EP EP06813554A patent/EP1928506A4/en not_active Withdrawn
- 2006-08-18 RU RU2008110494/10A patent/RU2515108C2/ru not_active IP Right Cessation
- 2006-08-18 CN CN2006800390523A patent/CN101370525B/zh not_active Expired - Fee Related
- 2006-08-18 EP EP12161953A patent/EP2500352A1/en not_active Withdrawn
- 2006-08-18 CA CA2618482A patent/CA2618482C/en not_active Expired - Fee Related
- 2006-08-18 NZ NZ612578A patent/NZ612578A/en not_active IP Right Cessation
- 2006-08-18 TW TW095130565A patent/TWI323734B/zh not_active IP Right Cessation
- 2006-08-18 NZ NZ597168A patent/NZ597168A/xx not_active IP Right Cessation
- 2006-08-18 EP EP12162014A patent/EP2495257A3/en not_active Withdrawn
- 2006-08-18 KR KR1020147009437A patent/KR20140053410A/ko not_active Application Discontinuation
- 2006-08-18 EP EP12162041A patent/EP2520588A1/en not_active Withdrawn
- 2006-08-18 JP JP2008527180A patent/JP5364870B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-14 IL IL189543A patent/IL189543A/en not_active IP Right Cessation
- 2008-03-17 NO NO20081354A patent/NO20081354L/no not_active Application Discontinuation
-
2011
- 2011-01-26 ZA ZA2011/00659A patent/ZA201100659B/en unknown
-
2013
- 2013-08-14 ZA ZA2013/06105A patent/ZA201306105B/en unknown
-
2014
- 2014-03-21 RU RU2014110927/10A patent/RU2014110927A/ru not_active Application Discontinuation
- 2014-05-15 IL IL232646A patent/IL232646A0/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0517024A2 (de) * | 1991-06-03 | 1992-12-09 | BEHRINGWERKE Aktiengesellschaft | Tetravalente bispezifische Rezeptoren, ihre Herstellung und Verwendung |
WO1995009917A1 (en) * | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US20020127231A1 (en) * | 1996-03-28 | 2002-09-12 | Jonathan Schneck | Soluble divalent and multivalent heterodimeric analogs of proteins |
WO2001077342A1 (en) * | 2000-04-11 | 2001-10-18 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2002002781A1 (en) * | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
WO2006020258A2 (en) * | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
Non-Patent Citations (7)
Title |
---|
DIGIAMMARINO E L ET AL: "Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design", MABS, LANDES BIOSCIENCE, US, vol. 3, no. 5, 1 September 2011 (2011-09-01), pages 487 - 494, XP009168882, ISSN: 1942-0862 * |
JAKOB CLARISSA G ET AL: "Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig (TM)) molecule", MABS, vol. 5, no. 3, May 2013 (2013-05-01), pages 358 - 363, ISSN: 1942-0862(print) * |
LU DAN ET AL: "Di-diabody: A novel tetravalent bispecific antibody molecule by design.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 279, no. 1-2, August 2003 (2003-08-01), pages 219 - 232, XP004455322, ISSN: 0022-1759 * |
M. A. AYOUB ET AL: "Preferential Formation of MT1/MT2 Melatonin Receptor Heterodimers with Distinct Ligand Interaction Properties Compared with MT2 Homodimers", MOLECULAR PHARMACOLOGY, vol. 66, no. 2, 1 August 2004 (2004-08-01), pages 312 - 321, XP055031646, ISSN: 0026-895X, DOI: 10.1124/mol.104.000398 * |
PARK S S ET AL: "Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 37, no. 18, 1 December 2000 (2000-12-01), pages 1123 - 1130, XP002266827, ISSN: 0161-5890 * |
See also references of WO2007024715A2 * |
WU CHENGBIN ET AL: "Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin", NATURE BIOTECHNOLOGY, vol. 25, no. 11, November 2007 (2007-11-01), pages 1290 - 1297, XP002542446, ISSN: 1087-0156 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL232646A0 (en) | Immunoglobulin dual variable domain and its uses | |
EP2056869A4 (en) | VARIABLE DOUBLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF | |
IL222922A (en) | Antibodies against neurophilin-1 and their use | |
IL189609A0 (en) | 4-substituted pyrrolidin-2-ones and their use | |
AP2008004471A0 (en) | Anti-Alpha2 Intergin antibodies and their uses | |
EP1802588A4 (en) | SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF | |
EP1951680A4 (en) | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | |
GB0512940D0 (en) | Compounds and their use | |
AU2006339063A8 (en) | Macro-diacrylates and macro-polyacrylates | |
IL184024A0 (en) | Irta-5 antibodies and their uses | |
EP1872448A4 (en) | POSITIONING ASSEMBLY AND MULTIPLE SWITCHING | |
GB0520743D0 (en) | Compounds and their use | |
IL189252A0 (en) | Dihydroxyanthraquinones and their use | |
IL185308A0 (en) | Replikin peptides and uses thereof | |
EP1912921A4 (en) | COMPOUNDS ON TETRAAZAPORPHYRINBASE AND ITS USES | |
EP1848438A4 (en) | DIAMINOPHENOTHIAZINE COMPOSITIONS AND THEIR USE | |
IL185223A0 (en) | Compounds and uses thereof | |
EP1943350A4 (en) | LATENT PROCYTOTOXINS AND USES THEREOF | |
EP2184793A4 (en) | SWITCHING ELEMENT AND ITS APPLICATION | |
GB0525380D0 (en) | SRCR-B domain containing proteins | |
GB0516571D0 (en) | Novel polypeptides and uses thereof | |
GB2422232B (en) | Course and sail-plan predictor | |
GB0515688D0 (en) | Compounds and their uses | |
GB0506545D0 (en) | Compounds and their uses | |
GB0510263D0 (en) | Compounds and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080317 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
R17D | Deferred search report published (corrected) |
Effective date: 20081030 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 51/00 20060101AFI20081114BHEP Ipc: A61M 36/14 20060101ALI20081114BHEP Ipc: C12Q 1/68 20060101ALI20081114BHEP |
|
RAX | Requested extension states of the european patent have changed |
Extension state: RS Payment date: 20080328 Extension state: MK Payment date: 20080328 Extension state: HR Payment date: 20080328 Extension state: BA Payment date: 20080328 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090921 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 51/00 20060101AFI20081114BHEP Ipc: C07K 16/28 20060101ALI20090914BHEP Ipc: C07K 16/24 20060101ALI20090914BHEP Ipc: C12Q 1/68 20060101ALI20090914BHEP Ipc: A61M 36/14 20060101ALI20090914BHEP |
|
17Q | First examination report despatched |
Effective date: 20100323 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: EL |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ABBVIE INC. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150331 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160502 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170215 |
|
INTG | Intention to grant announced |
Effective date: 20170222 |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20170307 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170905 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180116 |